Abstract
Anthracyclines have a central role in the management of non-Hodgkin's lymphoma (NHL). The cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment regimen has been the standard of care for more than 20 years. Further improvements have been made to the efficacy of this chemotherapy by reducing the dosing interval and adding rituximab to the regimen. A major limitation to the use of anthracyclines is the development of cardiotoxicity as a late adverse event. Strategies to reduce cardiac events include changes to the dosing schedule for doxorubicin, use of the chelating agent dexrazoxane and the use of liposome-encapsulated doxorubicin. This latter strategy has demonstrated good efficacy and reduced cardiotoxicity in patients with NHL, including those at risk of developing cardiac effects.
| Original language | English |
|---|---|
| Pages (from-to) | 1-3 |
| Number of pages | 3 |
| Journal | Hematology Reports |
| Volume | 3 |
| Issue number | 3 SUPPL. |
| DOIs | |
| Publication status | Published - 2011 |
Fingerprint
Keywords
- Anthracycline
- Doxorubicin
- Liposomal doxorubicin
- Non-Hodgkin's lymphoma
ASJC Scopus subject areas
- Hematology
Cite this
Moving forward with new data and approaches : A fresh look at anthracyclines in non-Hodgkin's lymphoma. / Amadori, Dino.
In: Hematology Reports, Vol. 3, No. 3 SUPPL., 2011, p. 1-3.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Moving forward with new data and approaches
T2 - A fresh look at anthracyclines in non-Hodgkin's lymphoma
AU - Amadori, Dino
PY - 2011
Y1 - 2011
N2 - Anthracyclines have a central role in the management of non-Hodgkin's lymphoma (NHL). The cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment regimen has been the standard of care for more than 20 years. Further improvements have been made to the efficacy of this chemotherapy by reducing the dosing interval and adding rituximab to the regimen. A major limitation to the use of anthracyclines is the development of cardiotoxicity as a late adverse event. Strategies to reduce cardiac events include changes to the dosing schedule for doxorubicin, use of the chelating agent dexrazoxane and the use of liposome-encapsulated doxorubicin. This latter strategy has demonstrated good efficacy and reduced cardiotoxicity in patients with NHL, including those at risk of developing cardiac effects.
AB - Anthracyclines have a central role in the management of non-Hodgkin's lymphoma (NHL). The cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment regimen has been the standard of care for more than 20 years. Further improvements have been made to the efficacy of this chemotherapy by reducing the dosing interval and adding rituximab to the regimen. A major limitation to the use of anthracyclines is the development of cardiotoxicity as a late adverse event. Strategies to reduce cardiac events include changes to the dosing schedule for doxorubicin, use of the chelating agent dexrazoxane and the use of liposome-encapsulated doxorubicin. This latter strategy has demonstrated good efficacy and reduced cardiotoxicity in patients with NHL, including those at risk of developing cardiac effects.
KW - Anthracycline
KW - Doxorubicin
KW - Liposomal doxorubicin
KW - Non-Hodgkin's lymphoma
UR - http://www.scopus.com/inward/record.url?scp=82755182374&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=82755182374&partnerID=8YFLogxK
U2 - 10.4081/hr.2011.s3.e1
DO - 10.4081/hr.2011.s3.e1
M3 - Article
C2 - 22586509
AN - SCOPUS:82755182374
VL - 3
SP - 1
EP - 3
JO - Hematology Reports
JF - Hematology Reports
SN - 2038-8322
IS - 3 SUPPL.
ER -